Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MaxCyte, Inc. (MXCT : NSDQ)

• Company Description    MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland. Number of Employees: 84

• Price / Volume Information    Yesterday's Closing Price: $4.45 Daily Weekly Monthly 20 Day Moving Average: 621,816 shares Shares Outstanding: 101.54 (millions) Market Capitalization: $451.85 (millions) Beta: 52 Week High: $17.44 52 Week Low: $4.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.29% -9.37% 12 Week -34.94% -29.41% Year To Date -56.33% -48.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 22 FIRSTFIELD ROAD SUITE 250 - GAITHERSBURG,MD 20878 USA ph: 301-944-1700 fax: 301-944-1703 ir@maxcyte.com None

• General Corporate Information    Officers Douglas Doerfler - Chief Executive Officer and President Richard Douglas - Chairman Ron Holtz - Chief Financial Officer Ron Holtz - Senior Vice President and Chief Accounting Officer Maher Masoud - Executive Vice President; General Counsel and Secr Peer Information MaxCyte, Inc. (CORR.) MaxCyte, Inc. (RSPI) MaxCyte, Inc. (CGXP) MaxCyte, Inc. (BGEN) MaxCyte, Inc. (GTBP) MaxCyte, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 57777K106 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/12/22 Share - Related Items Shares Outstanding: 101.54 Most Recent Split Date: (:1) Beta: Market Capitalization: $451.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.72 Price/Cash Flow: - Price / Sales: 11.59 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 20.00% Sales Growth vs. Year Ago Period: 78.40% vs. Previous Quarter: 14.14% ROE 03/31/22 - -7.39 12/31/21 - -11.11 09/30/21 - -14.74 ROA 03/31/22 - -6.78 12/31/21 - -10.18 09/30/21 - -13.03 Current Ratio 03/31/22 - 17.09 12/31/21 - 17.32 09/30/21 - 21.43 Quick Ratio 03/31/22 - 16.67 12/31/21 - 16.98 09/30/21 - 21.10 Operating Margin 03/31/22 - -41.15 12/31/21 - -56.30 09/30/21 - -52.27 Net Margin 03/31/22 - -41.15 12/31/21 - -56.30 09/30/21 - -52.27 Pre-Tax Margin 03/31/22 - -41.15 12/31/21 - -56.30 09/30/21 - -52.27 Book Value 03/31/22 - 2.58 12/31/21 - 2.61 09/30/21 - 2.63 Inventory Turnover 03/31/22 - 0.80 12/31/21 - 0.81 09/30/21 - 0.78 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©